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Background: The Swedish National Patient Register offers unique possibilities for identification of large cohorts,
such as patients with rheumatoid arthritis (RA). Although the overall diagnostic validity in the register has been
reported as good, the aims of this study were to a) specifically validate the RA diagnosis from contemporary
outpatient specialist care in this register, and b) assess the proportion of patients identified via algorithms to define
incident RA in the register who in clinical practice also have new-onset disease.
Methods: 211 individuals with prevalent or incident RA in the National Patient Register were included. By
extracting diagnosis-related parameters from their medical records, we determined if the patient fulfilled the 2010
ACR/EULAR- and the 1987 ACR-classification criteria for RA. We also determined whether clinical diagnosis was
synchronous with disease onset as defined through register-based algorithms.
Results: For 91% of the prevalent patients, the RA diagnosis in the National Patient Register fulfilled classification
criteria or clinical diagnosis for RA. Among individuals identified with incident RA using a strict algorithm for
new-onset disease, the RA diagnosis was substantiated in 91%, of whom 92% also represented new-onset disease.
Conclusions: The validity of the RA diagnosis in the National Patient Register was high and, by using specific
algorithms, new-onset RA can be defined. These findings strengthen the notion that the National Patient Register
may be used to define RA populations with high validity to allow for high-quality epidemiological studies.
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The extensive and high-quality Swedish health informa-
tion network together with a population-based public
health care system enables register-based epidemiological
studies. For instance, studies on patients with rheumatoid
arthritis (RA) have contributed to our understanding
of the descriptive epidemiology of RA [1-5] and of sev-
eral different aspects of the disease, its treatment and
outcomes thereof [6-13]. In these studies the Swedish
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to identify patients with RA.
Hospital discharges from inpatient care and patients
visits in non-primary outpatient care are registered in
the National Patient Register. The register also includes
the diagnosis in question, coded according to the Inter-
national Classification of Diseases (ICD). The validity of
the diagnosis codes for RA as assigned on discharge notes
from hospitalization has previously been investigated [14].
However, only ad hoc and study-specific validations of diag-
nosis codes for RA from the outpatient component of the
National Patient Register have been performed [15]. Since
the vast majority of patients with RA are nowadays
treated in outpatient care, it is important to assess the
validity (or positive predictive value) of this component
of the National Patient Register. In addition, register-tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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to onset of disease. Apart from validating the register-
based RA diagnosis per se, it is also important to valid-
ate register-based algorithms to define incident RA.
The aims of this study were therefore to assess:
a) the proportion of unselected (prevalent) patients
listed with a RA-specific diagnosis from contemporary
outpatient care in the National Patient Register who
also fulfill formal classification criteria or a clinical
diagnosis of RA
b) the proportion of patients identified with incident
RA who also have new-onset (incident) disease,
using register-based algorithms.
To do this, we used the National Patient Register to identify
prevalent and incident cases with RA. Chart abstraction
was used to validate these register-based diagnoses against
both classification criteria and clinical diagnoses. This is be-
cause classification criteria are not equal to diagnosis criteria.
Methods
Design and setting
The Swedish personal identification number is a 10-digit
number unique to every Swedish resident. The National
Patient Register, the Prescribed Drug Register and the
medical files all contain the personal identification number,
allowing for deterministic record linkage.
In Sweden, hospital-based rheumatologists treat the ma-
jority of all patients with RA. The Karolinska University
Hospital in Stockholm houses the largest Rheumatology
department in Sweden, providing around two thirds of all
rheumatology care in the geographically defined Stockholm
County Council (20% of the entire country).
Data sources used
The national patient register
Hospital discharges from inpatient care have been regis-
tered since 1964 and patient visits in non-primary out-
patient care since 2001. Diagnoses are coded according to
the ICD. The coverage of inpatient discharges is close to
100% [16], whereas the coverage of outpatient discharges
is around 87% [17]. The latter is higher for somatic care
such as Rheumatology and for public care providers.
The prescribed drug register
The National Board of Health and Welfare maintain the
Prescribed Drug Register. It contains information about
all drugs dispensed on prescription in Sweden since
2005. The coverage is close to 100% (although in-hospital
medication prescribed through non-electronic requisition
is not included).
For this study, we identified two groups of patients from
the National Patient Register, one with ‘prevalent’ RA andone with ‘incident’ RA. RA was defined as at least one list-
ing with a primary or secondary ICD-10 diagnosis code
of seropositive RA (M05.9) or seronegative RA (M06.0)
between 2005 and 2008 at a non-primary outpatient
care facility at the Karolinska University Hospital. Since
the review period in the medical record was set to three
years after being diagnosed with RA, the study period
stretched from 2005 through 2012. In total, 211 patients
were randomly extracted from the National Patient Register,
equally allocated to a group of incident (according to an
algorithm described below) and a group of prevalent RA.
Ethical approval was granted by the Regional Ethics
Committee, Karolinska Institutet, Stockholm, Sweden.
Reference number: DNR 2009/2005-31/3.
Validation of the register-based diagnosis of RA in
prevalent patients
The prevalent group consisted of 100 individuals defined
as patients with two or more visits to a rheumatologist
between 2005 and 2008, listing an ICD code for RA.
The diagnosis was evaluated at the date of the second
consecutive visit with RA according to the National
Patient Register.
We developed a 20-item form to abstract diagnosis-
related parameters [see Additional file 1]. By abstracting
these parameters, it was possible to determine if the pa-
tient fulfilled the 2010 American College of Rheumatology
(ACR)/European League Against Rheumatism (EULAR)
classification criteria [18] and the 1987 ACR classification
criteria [19] for RA. The criteria will be referred to as 2010
ACR/EULAR and 1987 ACR respectively in this text. Cur-
rently, both criteria are used in Swedish clinical practice to
classify RA. In addition to the classification criteria, the fol-
lowing parameters were abstracted from the medical records:
1) Whether radiographic erosions had occurred
either at a) the date the patient fulfilled the register
based definition of prevalent RA (i.e. at the second
visit listing this diagnosis), or at b) the end of the
study period (three years later).
2) Whether the prevalent patient would clinically be
regarded as having RA although not formally
fulfilling the classification criteria at date of
evaluation, or vice versa.
In those patients not fulfilling classification criteria or
clinical diagnoses of RA, we also charted the alternative
diagnoses in both the prevalent and incident group.
Validation of the register-based diagnosis of RA in
incident patients
The incident group consisted of 111 individuals defined
as patients with their first ever visit to a rheumatologist
in 2008, listing a RA diagnosis code using data from the
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definition of incident RA, a strict definition of the register-
based definition of incident RA was also explored. This
definition required fulfillment of two additional criteria:
1) A second hospital visit for RA within one year after
the first visit
2) No DMARD treatment more than 6 months before
the first visit with RA diagnosis.
Information from the National Patient Register and the
Prescribed Drug Register was used to identify patients
with this strict algorithm.
Similar to the abstraction form used for evaluation of
cases with a register-based definition of prevalent RA,
we developed a 21-item form for patients with incident
disease [see Additional file 2]. For the incident group the
diagnosis was validated at ‘the incident time point’, the
date of the first visits listing a diagnosis code for RA.
We determined if the patient would clinically be regarded
as having a new-onset (incident) disease, based on the
medical history and the date of onset of RA symptoms.
The abstraction forms were compiled manually. In
addition to classification criteria, the following parameters
were extracted from the medical records:
1) Whether radiographic erosions had occurred either
at a) date of first visit, or b) two years after the first
visit
2) Whether the RA diagnosis remained two years after
the first visit
3) Date of onset of RA symptoms
Results
The age and sex distribution of all patients compared to
those with verified RA were similar, but with higher
proportion of seropositive RA among the verified RA
patients (Table 1).
Prevalent patients (n = 100)
Of the 100 patients identified as ‘prevalent RA’ in the
National Patient Register, medical records for all wereTable 1 Characteristics of the register-identified prevalent an
Prevalent RA
All patients Verified RA
N 100 91
Women, n (%) 72 (72%) 64 (70%)
Age
- Mean (SD) 57.9 (16.1) 58.4 (16.1)
- Median (25th-75th) 58.4 (46.3-69.0) 59.1 (46.5-71.5)
RF positive, n (%) 85 (85%) 80 (88%)available for review. According to our register-based def-
inition, chart review indicated that 91 (91%) were cor-
rectly diagnosed with RA. All but one of the remaining
nine patients who did not have RA suffered from an-
other inflammatory rheumatic disease (Table 2). Among
the verified RA cases, 72 (79%) fulfilled both classifica-
tion criteria for RA. In the seropositive subset (listed
with an ICD-10 diagnosis code of seropositive/RF-posi-
tive RA), 80 out of 85 (94%) were correctly diagnosed
with RA by at least one of the classification criteria. Of
these, 50 (82%) fulfilled both classification criteria. Six
patients did not fulfill the classification criteria at the
date of evaluation. These all had a typical symmetric in-
flammatory polyarthritis and all the available information
supported the diagnosis of RA. For these individuals,
either of the classification criteria was generally fulfilled at
a later stage.
Forty-two (50%) of the patients with a verified RA-
diagnosis had an erosive disease at the end of the observa-
tion period.
Incident patients (n = 111)
Of the 111 patients identified with ‘incident RA’, 9 patients
could not be validated because of an incomplete medical
record with missing data. Hence they were excluded
(Table 3).
Chart review of the remaining patients indicated that
85 out of 102 patients (83%) were correctly coded with
RA at date of first visit and remained so after the two-
year follow-up period. Similar figures could be observed
for the seropositive subgroup (63 out of 70; 90%). Of the
patients whose RA diagnosis could not be substantiated,
all suffered from another rheumatic disease according to
their medical records (Table 3). Six patients fulfilled one
or both of the classification criteria at date of first visit
but not after the two-year follow-up period. For five of
these cases, the initial RA diagnosis was changed to an-
other rheumatic disease (Table 3).
Of the patients with verified RA diagnoses, 73 out of
85 (86%) also fulfilled our register-based base-case defin-
ition of ‘incident’ disease and did not develop any alter-
native explanation for their disease during the two yearsd incident RA patients
Incident RA
All patients Verified RA Verified incident RA
102 85 73
77 (75%) 65 (76%) 53 (73%)
57.7 (17.4) 58.6 (17.3) 58.4 (17.8)
60.0 (45.3-72.0) 60.7 (45.8-74.1) 60.7 (45.8-73.9)
70 (69%) 63 (74%) 53 (73%)
Table 2 Summary of medical records of prevalent
patients registered with RA in the Swedish National
Patient Register
Total number of subjects 100
Verified RA 91(91%)
1987 ACR and 2010 ACR/EULAR criteria 72/91(79%)
1987 ACR criteria only 9/91(9.9%)
2010 ACR/EULAR criteria only 4/91(4.4%)
RA diagnosis not substantiated 9(9%)





n, values given as number of patients and (%) given as the
equivalent percentage.
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patients were considered to be ‘prevalent’ since they all
had a long-time history of RA, and had to a large extent
been treated previously by a rheumatologist practicing
outside the hospital. Among the verified incident RA
cases 61 (84%) fulfilled both classification criteria for
RA. Two of the incident RA cases fulfilled neither of the
classification criteria at the date of evaluation, because
information about the exact number of joints involved
was lacking or the patient had palindromic rheumatism.
However all the available information supported theTable 3 Summary of medical records of incident patients
in the base-case definition registered with RA in the
Swedish National Patient Register
Total number of subjects 111
Incomplete medical record 9
Subjects amenable for validation 102(100%)
Verified RA 85(83%)
Thereof incident 73(86%)
1987 ACR criteria and 2010 ACR/EULAR criteria 61/73(84%)
1987 ACR criteria only 9/73(12%)
2010 ACR/EULAR criteria only 1/73(1.4%)
RA diagnosis not substantiated 17(17%)
Psoriatic arthritis 6




Systemic lupus erythematosus 1
Inflammatory systemic disease 1
Polymyalgia rheumatica 1
n, values given as number of patients and (%) given as the
equivalent percentage.diagnosis of RA. In some cases, there were missing data
at the time point of evaluating the classification criteria,
mainly about the existence of rheumatoid nodules and
radiographic changes. Nevertheless they fulfilled the
classification criteria and the missing data did not affect
the outcome in these cases. Twenty-six patients (38%) of
the verified incident RA cases had erosive disease at
their first visit or developed erosive disease during the
first two years after being diagnosed with RA. The me-
dian number of months between onsets of symptoms
described in the medical file and recorded RA diagnosis
in the National Patient Register was 6.7 months.
In the subgroup (n = 82) of patients identified as inci-
dent RA according to our ‘strict’ definition (Table 4), 75
(91%) were correctly diagnosed with RA. Of these, 69
(92%) were also incident.
Discussion
The main findings of this study show that the validity of
the register-based RA diagnosis was as high as 90% for
prevalent RA and around 90% among cases identified,
using strict algorithms to define incident RA.
There was no substantial difference in the validity when
using the 1987 ACR or 2010 ACR/EULAR classification
criteria, as the vast majority of patients fulfilled both. The
number of patients classified with RA increased by ap-
proximately 10% when including patients only, fulfilling
one of the two sets of classification criteria. The 2010
ACR/EULAR criteria were introduced to detect RA at an
earlier phase than the 1987 ACR criteria [20]. However,
somewhat counterintuitively, the majority of patients ful-
filling only one of the two criteria in this study fulfilled the
1987 ACR criteria. These patients had mostly a seronega-
tive RA with few joints involved. The patients only fulfill-
ing the 2010 ACR/EULAR criteria were mostly patients
with high positive anti-CCP or high positive RF and ele-
vated ESR. Examining the medical records in some cases
showed that the routine for documentation of jointTable 4 Summary of medical records of incident patients
in the strict definition of register-based incident RA in the
Swedish National Patient Register
Total number of subjects 82
Verified RA 75(91%)
Thereof incident 69(92%)
1987 ACR criteria and 2010 ACR/EULAR criteria 60/69(87%)
1987 criteria only 6/69(87%)
2010 ACR/EULAR criteria only 1/69(1.4%)
RA diagnosis not substained 7(8.5%)
Psoriatic arthritis 3
Unspecified polyarthritis 4
n, values given as number of patients and (%) given as the
equivalent percentage.
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the 2010 ACR/EULAR criteria, which may have given rise
to this result.
The validity was somewhat higher among patients re-
ceiving diagnosis codes for seropositive (vs. seronega-
tive) disease. This is expected, as serological markers
contribute to the classification criteria used as part of
the ‘gold standard’.
Interestingly, we also noted that all patients but one who
were incorrectly coded with RA suffered from another de-
fined inflammatory rheumatic disease rather than unspe-
cific arthralgia or osteoarthritis. These included Psoriatic
Arthritis, Granulomatosis with polyangiitis (Wegener’s
granulomatosis) and unspecified polyarthritis.
The prevalent patients with RA were required to have
at least two visits to the department of rheumatology.
Although the majority of the patients with prevalent RA
had a long history of RA, a few of the prevalent patients
(n = 9) had their two (first ever) visits close in time and
were therefore also eligible as incident RA.
Since RA is a chronic disease and a long-lasting condi-
tion, the diagnosis can usually be verified over time.
Some cases that fulfill the classification criteria for RA at
one time point may at a later time point have developed
another diagnosis than RA (e.g. Psoriatic Arthritis). A
major strength of this study was the additional verifica-
tion of the RA diagnosis for the incident patients
through the follow-up visits approximately two years
after the first visit. In this way it was possible to verify
‘genuine’ RA cases. However, using this gold standard
may have resulted in an underestimation of the still good
diagnostic accuracy. This is because the standard en-
sures that incident patients should not only have re-
ceived a clinical diagnosis or fulfill the classification
criteria at the ‘incident time point’ but they should also
have retained their RA diagnosis after two years to be
classified as having RA.
To our knowledge, previous validations of RA diagno-
ses in the outpatient component of the National Patient
Register have been study-specific. Our present findings
show a validity that correspond well to figures shown in
one of the study-specific validations where over 90% of
all diagnoses of an inflammatory poly-arthritide (RA
M05 or M06, or other inflammatory poly-arthritis, M13)
were correct [15]. Since the structure and coverage of
health information networks and administrative databases
differ between countries, our findings are not entirely
comparable with similar international studies. However,
the validity of an RA diagnosis among RA-coded individ-
uals in the General Practice Research Database (database
of primary care medical records in the UK-population)
appears high for patients with specific characteristics.
Using a data-derived diagnostic algorithm with a > 80%
sensitivity and specificity, 61% of RA-coded patientsfulfilled the diagnostic algorithm [21]. Another valid-
ation study using the medical records of rheumatolo-
gists in Ontario, Canada showed a high level of accuracy
when using administrative data to identify RA patients.
Most RA patients (84%) had an RA diagnosis present in
the administrative data within +/− one year of a rheu-
matologist’s documented diagnosis date [22]. One retro-
spective chart abstraction study from the same area
showed a positive predictive value ranging from 51-83%
amongst the primary care sample, and ranging from 55-
80% in the rheumatology sample, depending on the
diagnostic algorithm used [23]. One study of discharge
diagnoses for patients with RA recorded in the Danish
National Patient Registry, showed an overall validity of
59%. However, major differences of the validity were seen
depending on the characteristics of the underlying hos-
pital registrations [24]. The design of our study allowed us
to assess the positive predictive value of RA. In addition to
the disease prevalence in the study sample the predictive
values depend on the sensitivity and specificity of the diag-
nostic algorithm. Our study was not designed to assess
sensitivity, specificity, nor the negative predictive value,
however these could have been helpful validity measures.
To this end, we note with interest that in previous studies
of RA using data from the National Patient Register and
from the Swedish Rheumatology Quality Register, the net
contribution of patients from the latter was only 1%, sug-
gesting a high coverage (‘sensitivity’) of the former.
One limitation of this study is the restricted number of
patients. Although the Rheumatology department at the
Karolinska University Hospital is the largest in Sweden,
these results may not be generalized to the whole country.
Nevertheless, validity data from this site is important, as it
serves the vast majority of the country’s largest catchment
area.
Besides the data sources used, the result of this study
was based on the information given in the medical re-
cords. Therefore, the quality of the registration performed
by the rheumatologist in the medical record significantly
impacted the outcome. For example, a structured docu-
mentation of joint involvement was a prerequisite for
validation of the classification criteria. This is why a few
patients (N = 9) were excluded since the medical record
was incomplete.
Conclusions
Based on medical records from patients coded with RA in
the National Patient Register in Stockholm County, the
validity of the RA diagnosis was high both in prevalent
patients and for patients identified with new-onset RA.
These findings strengthen the notion that the National
Patient Register and data algorithms may be used to
define RA populations with a sufficiently high validity to
allow for high-quality epidemiological studies.
Waldenlind et al. BMC Musculoskeletal Disorders 2014, 15:432 Page 6 of 6
http://www.biomedcentral.com/1471-2474/15/432Additional files
Additional file 1: Abstraction form for validation of Rheumatoid
Arthritis diagnosis in the Swedish National Patient Register:
Prevalent patients.
Additional file 2: Abstraction form for validation of Rheumatoid
Arthritis diagnosis in the Swedish National Patient Register:
Incident patients.
Abbreviations
RA: Rheumatoid arthritis; ACR: American College of Rheumatology;
EULAR: European League Against Rheumatism; ICD: International
Classification of Diseases.
Competing interests
Johan Askling has received research grants from Pfizer and AstraZeneca.
Jonas Eriksson and Johan Askling reported participating in research projects
fully or partly funded by Novo Nordisk and COMBINE Sweden.
Authors’ contributions
KW had full access to all of the data in the study and takes responsibility for
the accuracy of the data analysis. Data collection and quality control of data:
JE, KW, JA. Analysis and interpretation of data: KW, JA. Drafting of the
manuscript: KW. Critical revision of the manuscript for important intellectual
contents: All authors. Clinical aspects on the interpretation of data: BG. Study
supervision: JA. All authors read and approved the final manuscript.
Acknowledgement
This study was funded through grants from the Swedish Research Council,
the Swedish Foundation for Strategic Research, and from the public-private
COMBINE research consortium.
Received: 15 April 2014 Accepted: 8 December 2014
Published: 15 December 2014
References
1. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius
N, Lindblad S, Klareskog L: Swedish registers to examine drug safety and
clinical issues in RA. Ann Rheum Dis 2006, 65(6):707–712.
2. Eriksson JK, Neovius M, Ernestam S, Lindblad S, Simard JF, Askling J: Incidence
of rheumatoid arthritis in Sweden: a nationwide population-based
assessment of incidence, its determinants, and treatment penetration.
Arthritis Care Res 2013, 65(6):870–878.
3. Neovius M, Simard J, Sundstrom A, Jacobsson L, Geborek P, Saxne T,
Feltelius N, Klareskog L, Askling J, Group AS: Generalisability of clinical
registers used for drug safety and comparative effectiveness research:
coverage of the Swedish Biologics Register. Ann Rheum Dis 2011,
70(3):516–519.
4. Neovius M, Simard JF, Askling J: group As: Nationwide prevalence of
rheumatoid arthritis and penetration of disease-modifying drugs in
Sweden. Ann Rheum Dis 2011, 70(4):624–629.
5. Neovius M, Sundstrom A, Simard J, Wettermark B, Cars T, Feltelius N, Askling J,
Klareskog L, Group AS: Small-area variations in sales of TNF inhibitors in
Sweden between 2000 and 2009. Scand J Rheumatol 2011, 40(1):8–15.
6. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson
L, Coster L, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S,
Saxne T, van Vollenhoven R, Klareskog L, Feltelius N: Anti-tumour necrosis
factor therapy in rheumatoid arthritis and risk of malignant lymphomas:
relative risks and time trends in the Swedish Biologics Register.
Ann Rheum Dis 2009, 68(5):648–653.
7. Askling J, Dixon W: The safety of anti-tumour necrosis factor therapy in
rheumatoid arthritis. Curr Opin Rheumatol 2008, 20(2):138–144.
8. Askling J, Dixon W: Influence of biological agents on cardiovascular
disease in rheumatoid arthritis. Ann Rheum Dis 2011, 70(4):561–562.
9. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Coster L,
Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S,
Saxne T, van Vollenhoven RF, Klareskog L: Time-dependent increase in risk
of hospitalisation with infection among Swedish RA patients treated
with TNF antagonists. Ann Rheum Dis 2007, 66(10):1339–1344.10. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund
E, Dackhammar C, Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S,
Rantapää-Dahlqvist S, Saxne T, Klareskog L: Cancer risk in patients with
rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies:
does the risk change with the time since start of treatment? Arthritis Rheum
2009, 60(11):3180–3189.
11. Raaschou P, Simard JF, Holmqvist M, Askling J, Group AS: Rheumatoid
arthritis, anti-tumour necrosis factor therapy, and risk of malignant
melanoma: nationwide population based prospective cohort study
from Sweden. BMJ 2013, 346:f1939.
12. Raaschou P, Simard JF, Neovius M, Askling J, Anti-Rheumatic Therapy in
Sweden Study G: Does cancer that occurs during or after anti-tumor necrosis
factor therapy have a worse prognosis? A national assessment of overall and
site-specific cancer survival in rheumatoid arthritis patients treated with
biologic agents. Arthritis Rheum 2011, 63(7):1812–1822.
13. Simard JF, Neovius M, Askling J, Group AS: Mortality rates in patients with
rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-
specific comparisons in the Swedish Biologics Register. Arthritis Rheum
2012, 64(11):3502–3510.
14. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI,
Rosenquist R, Feltelius N, Sundstrom C, Klareskog L: Association of chronic
inflammation, not its treatment, with increased lymphoma risk in
rheumatoid arthritis. Arthritis Rheum 2006, 54(3):692–701.
15. Knight A, Sandin S, Askling J: Increased risk of autoimmune disease in families
with Wegener's granulomatosis. J Rheumatol 2010, 37(12):2553–2558.
16. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C,
Heurgren M, Olausson PO: External review and validation of the Swedish
national inpatient register. BMC Public Health 2011, 11:450.
17. Socialstyrelsen: Kodningskvalitet i patientregistret – Ett nytt verktyg för att mäta
kvalitet; 2013 [http://www.socialstyrelsen.se/publikationer2013/2013-3-10]
18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd,
Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader
KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW,
Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW,
Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et al:
2010 Rheumatoid arthritis classification criteria: an American College
of Rheumatology/European League Against Rheumatism collaborative
initiative. Arthritis Rheum 2010, 62(9):2569–2581.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey
LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt
DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American
Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988, 31(3):315–324.
20. Biliavska I, Stamm TA, Martinez-Avila J, Huizinga TW, Landewe RB, Steiner G,
Aletaha D, Smolen JS, Machold KP: Application of the 2010 ACR/EULAR
classification criteria in patients with very early inflammatory arthritis:
analysis of sensitivity, specificity and predictive values in the SAVE study
cohort. Ann Rheum Dis 2013, 72(8):1335–1341.
21. Thomas SL, Edwards CJ, Smeeth L, Cooper C, Hall AJ: How accurate are
diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the
general practice research database? Arthritis Rheum 2008, 59(9):1314–1321.
22. Widdifield J, Bernatsky S, Paterson JM, Tu K, Ng R, Thorne JC, Pope JE,
Bombardier C: Accuracy of Canadian health administrative databases in
identifying patients with rheumatoid arthritis: a validation study using the
medical records of rheumatologists. Arthritis Care Res 2013, 65(10):1582–1591.
23. Widdifield J, Bombardier C, Bernatsky S, Paterson JM, Green D, Young J,
Ivers N, Butt DA, Jaakkimainen RL, Thorne JC, Tu K: An administrative data
validation study of the accuracy of algorithms for identifying rheumatoid
arthritis: the influence of the reference standard on algorithm performance.
BMC Musculoskelet Disord 2014, 15:216.
24. Pedersen M, Klarlund M, Jacobsen S, Svendsen AJ, Frisch M: Validity of
rheumatoid arthritis diagnoses in the Danish National Patient Registry.
Eur J Epidemiol 2004, 19(12):1097–1103.
doi:10.1186/1471-2474-15-432
Cite this article as: Waldenlind et al.: Validation of the rheumatoid
arthritis diagnosis in the Swedish National patient register: a cohort
study from Stockholm County. BMC Musculoskeletal Disorders 2014 15:432.
